Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to…
Oncology
-
-
Johnson & Johnson to acquire Halda Therapeutics for $3.05bn
Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a $3.05bn cash…
-
General Proximity and Daiichi Sankyo link on oncology
General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes. Daiichi…
-
AI breakthrough promises earlier prostate cancer diagnosis
According to Cancer Research UK, prostate cancer is the most common cancer among men in the UK, representing 28% of…
-
ESMO 2025: Sichuan-Kelun moves in breast cancer ADC space
18 October 2025 marked the presentation of the highly anticipated OptiTROP-Breast02 trial at the 2025 European Society for Medical Oncology…
-
Debiopharm and NetTargets to identify synergistic drug combos for ADCs
Swiss-based Debiopharm has formed a research partnership with South Korea-based AI drug discovery company NetTargets for the identification and development…
-
Health Canada grants NOC for AstraZeneca’s breast cancer therapy
Health Canada has issued a notice of compliance (NOC) for AstraZeneca’shuman epidermal growth factor receptor 2 (HER2)-directed antibody drug conjugate…
-
ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results…
-
Oceanpine Capital to acquire 80% equity stake in Beijing Jacoray
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for a total consideration of 200m…
-
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo(cemiplimab-rwlc) as an adjuvant…
